SG11202108220YA - Treatment of skin lesions and pruritus in prurigo nodularis patients - Google Patents

Treatment of skin lesions and pruritus in prurigo nodularis patients

Info

Publication number
SG11202108220YA
SG11202108220YA SG11202108220YA SG11202108220YA SG11202108220YA SG 11202108220Y A SG11202108220Y A SG 11202108220YA SG 11202108220Y A SG11202108220Y A SG 11202108220YA SG 11202108220Y A SG11202108220Y A SG 11202108220YA SG 11202108220Y A SG11202108220Y A SG 11202108220YA
Authority
SG
Singapore
Prior art keywords
pruritus
patients
treatment
skin lesions
prurigo nodularis
Prior art date
Application number
SG11202108220YA
Other languages
English (en)
Inventor
Christophe Piketty
Original Assignee
Galderma Holding SA
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Holding SA, Chugai Pharmaceutical Co Ltd filed Critical Galderma Holding SA
Publication of SG11202108220YA publication Critical patent/SG11202108220YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG11202108220YA 2019-01-28 2020-01-28 Treatment of skin lesions and pruritus in prurigo nodularis patients SG11202108220YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962797803P 2019-01-28 2019-01-28
US201962809404P 2019-02-22 2019-02-22
PCT/IB2020/050623 WO2020157636A1 (en) 2019-01-28 2020-01-28 Treatment of skin lesions and pruritus in prurigo nodularis patients

Publications (1)

Publication Number Publication Date
SG11202108220YA true SG11202108220YA (en) 2021-08-30

Family

ID=69467604

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108220YA SG11202108220YA (en) 2019-01-28 2020-01-28 Treatment of skin lesions and pruritus in prurigo nodularis patients

Country Status (14)

Country Link
US (2) US11236157B2 (es)
EP (1) EP3917617A1 (es)
JP (4) JP7410852B2 (es)
KR (1) KR20210122286A (es)
CN (1) CN113660981A (es)
AU (1) AU2020213978A1 (es)
BR (1) BR112021014854A2 (es)
CA (1) CA3127983A1 (es)
CL (1) CL2021001976A1 (es)
IL (1) IL285171A (es)
MX (1) MX2021009051A (es)
SG (1) SG11202108220YA (es)
TW (1) TW202043282A (es)
WO (1) WO2020157636A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4229083A1 (en) * 2020-10-15 2023-08-23 Intervet International B.V. Caninized antibodies to canine interleukin-31 receptor alpha
TW202304510A (zh) * 2021-04-07 2023-02-01 瑞士商葛德瑪控股公司 結節性癢疹之治療
CN118076636A (zh) * 2021-09-15 2024-05-24 德米拉公司 Il-13抑制剂用于治疗结节性痒疹
US20240141050A1 (en) * 2022-09-02 2024-05-02 Galderma Holding S.A. Treatments for prurigo nodularis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
FR2761994B1 (fr) 1997-04-11 1999-06-18 Centre Nat Rech Scient Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
EP2135953B1 (en) 1999-06-02 2014-04-23 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, Nr. 10
US20120220948A1 (en) 2008-04-18 2012-08-30 Ipsyrng Capital Development, Llc Ergonomic syringe
DE102007056240A1 (de) 2007-11-22 2009-05-28 Henke-Sass, Wolf Gmbh Spritze
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
DK3341056T3 (da) 2015-08-24 2022-09-12 Adamis Pharmaceuticals Corp Sprøjteindretninger
KR101900427B1 (ko) 2018-05-25 2018-09-20 송향숙 가압력 측정이 가능한 주사기용 보조그립

Also Published As

Publication number Publication date
US20220177568A1 (en) 2022-06-09
JP2023126909A (ja) 2023-09-12
TW202043282A (zh) 2020-12-01
JP7410852B2 (ja) 2024-01-10
CA3127983A1 (en) 2020-08-06
US11236157B2 (en) 2022-02-01
KR20210122286A (ko) 2021-10-08
BR112021014854A2 (pt) 2021-12-21
CL2021001976A1 (es) 2022-02-11
JP2023182834A (ja) 2023-12-26
US20200239563A1 (en) 2020-07-30
AU2020213978A1 (en) 2021-09-23
JP2021509103A (ja) 2021-03-18
JP2022028788A (ja) 2022-02-16
MX2021009051A (es) 2021-12-10
EP3917617A1 (en) 2021-12-08
CN113660981A (zh) 2021-11-16
JP7309816B2 (ja) 2023-07-18
WO2020157636A1 (en) 2020-08-06
IL285171A (en) 2021-09-30
JP7375252B2 (ja) 2023-11-07

Similar Documents

Publication Publication Date Title
IL285171A (en) Treatment of skin lesions and itching in patients with prurigo nodularis
IL293809A (en) Systems and methods for cosmetic treatment of the skin using ultrasound
IL264301A (en) Treatment of Fabry disease in ert-naive and ert-experienced patients
ZA201902910B (en) Pharmaceutical composition for use in the therapeutic treatment of cancer and complications of cancer
IL289167A (en) The history of 2h-indazole and their use in the treatment of diseases
SG11202000423XA (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
EP4090658A4 (en) THERAPEUTIC MEDICATIONS AND TREATMENT METHODS
IL281999A (en) YAP/TAZ-TEAD interaction inhibitors and their use in cancer therapy
IL266287A (en) Treatment of Krab's disease with umbilical cord blood transplantation (ucbt) and increased galactocarbosidase (galc) expression
EP3915985A4 (en) PYRROLOPYRIDINE DERIVATIVE AND ITS USE IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASE
IL283298A (en) Methods for dosage and treatment of B cell malignancies in adoptive cell therapy
EP3549596A4 (en) USE OF MICROCYSTINES FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE PREVENTION OR TREATMENT OF ORGANIC AND TISSUE FIBROSE DISEASES
GB202306894D0 (en) Therapeutic and prohylactic use of microoganisms
ZA201906964B (en) Prevention and/or treatment of inflammatory skin disease
GB201820994D0 (en) Methods of treatment and diagnosis of tumours
RS62825B1 (sr) Tirotricin za upotrebu u lečenju ili profilaksi telesnih mirisa i preparati za to
IL308992A (en) Cancer treatment in patients with soluble FR-alpha
EP4045086A4 (en) USE OF SUCCINATE AS A BIOMARKER IN THE DIAGNOSIS AND TREATMENT OF CANCER
IL290192A (en) Nitanin analogs and their use in the treatment of chronic and acute pain
ZA202109986B (en) Treatment of heart failure in human subjects
PL3797771T3 (pl) Rebamipid do stosowania w zapobieganiu i leczeniu celiakii
PL3797772T3 (pl) Rebamipid do zastosowania w zapobieganiu i leczeniu choroby Leśniowskiego-Crohna
MX2021007063A (es) Deutetrabenazina para el tratamiento de la discinesia en la paralisis cerebral.
MX2019015448A (es) Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar.
IL311672A (en) Dioxazines and their use in the treatment of GBA-related diseases